2015
DOI: 10.1016/j.lungcan.2015.04.002
|View full text |Cite
|
Sign up to set email alerts
|

Characteristics of clinical N0 metastatic non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(14 citation statements)
references
References 32 publications
0
12
0
2
Order By: Relevance
“…In stage IV NSCLC patients undergoing surgery, those with clinical N0 disease had an 18 month median 5-year survival compared to 11 months in those with any nodal disease, highlighting the importance of neoadjuvant chemoradiation in diminishing nodal disease in surgical candidates with advanced stage NSCLC (p<0.001). 37 In a study by Collaud et al, a similar trend is seen with tumor size, with T1–2 stage IV NSCLC patients who undergo resection having a median 5-year survival of 26 months compared to only 8 months in T3–4 patients (p=0.007). 38 Additionally, data suggest that the timing of metastatic disease development may affect survival, with metachronous oligometastatic stage IV NSCLC patients having improved survival as opposed to synchronous oligometastatic disease.…”
Section: Resultsmentioning
confidence: 75%
“…In stage IV NSCLC patients undergoing surgery, those with clinical N0 disease had an 18 month median 5-year survival compared to 11 months in those with any nodal disease, highlighting the importance of neoadjuvant chemoradiation in diminishing nodal disease in surgical candidates with advanced stage NSCLC (p<0.001). 37 In a study by Collaud et al, a similar trend is seen with tumor size, with T1–2 stage IV NSCLC patients who undergo resection having a median 5-year survival of 26 months compared to only 8 months in T3–4 patients (p=0.007). 38 Additionally, data suggest that the timing of metastatic disease development may affect survival, with metachronous oligometastatic stage IV NSCLC patients having improved survival as opposed to synchronous oligometastatic disease.…”
Section: Resultsmentioning
confidence: 75%
“…As reported in the majority of the series, one of the keys for a favorable outcome is the absence of mediastinal lymph node involvement. A recently published retrospective study including 761 patients collected over a 13-year period (10), reported that cN0 stage IV patients had statistically significant longer survival (11.9 months) compared to 7.2 months for cN1-3 (P<0.001). This survival difference was maintained also in the group of patients who received active treatment including surgery in 2.4% of the patients (18.3 months for the cN0 versus 11.4 months for the rest; P<0.001) but did not reached a significant statistical difference when EGFR mutation was present (37.9 months for cN0 versus 27.0 months for cN1-3).…”
Section: The Role For a Proper Selection Of Patientsmentioning
confidence: 98%
“…Tamura et al (10) suggested that certain type of adrenal metastasis may result from a lymphatic spread as adrenal metastasis are more frequent in those with cN1-3. On the contrary to the brain metastasis, for synchronous adrenal metastasis, the treatment strategy is to operate the primary tumor in the lung first and after, the adrenal lesion (15).…”
Section: Adrenal Metastasismentioning
confidence: 99%
“…Other prognostic factors are: N-stage disease, tumor size, organ site, disease free-interval greater than 6 months, RPA classification, the presence of extracranial metastases, type of pulmonary surgical resection, primary tumor histology, age, number of secondary lesions, previous adjuvant regimens. Concerning with N-stage, Tamura et al (27), in a retrospective cohort study involving 761 stage IV NSCLC patients, reported N0 patients presented a significant increased survival when compared to N1-3 ones (11.9 vs. 7.2 months, P<0.001), thus suggesting lymph node metastases were independent prognostic factors. Similarly, tumor size seems to strongly influence prognosis, as reported by Collaud et al (28) in a small retrospective single-centre study.…”
Section: Oligometastatic Disease: State Of Artmentioning
confidence: 98%